Showing results (301-310 of 395) with videos related to

Sort By:
Pageof 40
Blood|November 10, 2021
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemiaPetra Langerbeins, Can Zhang, Sandra Robrecht, et al.
Nature Communications|April 18, 2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Blood|October 22, 2015
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialKirsten Fischer, Jasmin Bahlo, Anna Maria Fink, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Leukemia & Lymphoma|September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemiaClemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Pageof 40